Use of convalescent plasma therapy in SARS patients in Hong Kong
Abstract In order to evaluate the efficacy of convalescent plasma therapy in the treatment of patients with severe acute respiratory syndrome (SARS), 80 SARS patients were given convalescent plasma at Prince of Wales Hospital, Hong Kong, between 20 March and 26 May 2003. Good outcome was defined as discharge by day 22 following the onset of SARS symptoms. Poor outcome was defined as death or hospitalization beyond 22 days. A higher day-22 discharge rate was observed among patients who were given convalescent plasma before day 14 of illness (58.3% vs 15.6%; P<0.001) and among those who were PCR positive and seronegative for coronavirus at the time of plasma infusion (66.7% vs 20%; P=0.001)..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2004 |
|---|---|
| Erschienen: |
2004 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:24 |
|---|---|
| Enthalten in: |
European journal of clinical microbiology & infectious diseases - 24(2004), 1 vom: 23. Dez., Seite 44-46 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Cheng, Y. [VerfasserIn] |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| BKL: | |
|---|---|
| Themen: |
Lactate Dehydrogenase Level |
| doi: |
10.1007/s10096-004-1271-9 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR008668876 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR008668876 | ||
| 003 | DE-627 | ||
| 005 | 20230519194909.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 201005s2004 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s10096-004-1271-9 |2 doi | |
| 035 | |a (DE-627)SPR008668876 | ||
| 035 | |a (SPR)s10096-004-1271-9-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q ASE |
| 084 | |a 44.43 |2 bkl | ||
| 084 | |a 44.75 |2 bkl | ||
| 100 | 1 | |a Cheng, Y. |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Use of convalescent plasma therapy in SARS patients in Hong Kong |
| 264 | 1 | |c 2004 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Abstract In order to evaluate the efficacy of convalescent plasma therapy in the treatment of patients with severe acute respiratory syndrome (SARS), 80 SARS patients were given convalescent plasma at Prince of Wales Hospital, Hong Kong, between 20 March and 26 May 2003. Good outcome was defined as discharge by day 22 following the onset of SARS symptoms. Poor outcome was defined as death or hospitalization beyond 22 days. A higher day-22 discharge rate was observed among patients who were given convalescent plasma before day 14 of illness (58.3% vs 15.6%; P<0.001) and among those who were PCR positive and seronegative for coronavirus at the time of plasma infusion (66.7% vs 20%; P=0.001). | ||
| 650 | 4 | |a Severe Acute Respiratory Syndrome |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Severe Acute Respiratory Syndrome |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Lactate Dehydrogenase Level |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Severe Acute Respiratory Syndrome Patient |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Wale Hospital |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Wong, R. |e verfasserin |4 aut | |
| 700 | 1 | |a Soo, Y. O. Y. |e verfasserin |4 aut | |
| 700 | 1 | |a Wong, W. S. |e verfasserin |4 aut | |
| 700 | 1 | |a Lee, C. K. |e verfasserin |4 aut | |
| 700 | 1 | |a Ng, M. H. L. |e verfasserin |4 aut | |
| 700 | 1 | |a Chan, P. |e verfasserin |4 aut | |
| 700 | 1 | |a Wong, K. C. |e verfasserin |4 aut | |
| 700 | 1 | |a Leung, C. B. |e verfasserin |4 aut | |
| 700 | 1 | |a Cheng, G. |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t European journal of clinical microbiology & infectious diseases |d Berlin : Springer, 1982 |g 24(2004), 1 vom: 23. Dez., Seite 44-46 |w (DE-627)SPR008661995 |w (DE-600)1459049-9 |x 1435-4373 |7 nnns |
| 773 | 1 | 8 | |g volume:24 |g year:2004 |g number:1 |g day:23 |g month:12 |g pages:44-46 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1007/s10096-004-1271-9 |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 912 | |a SSG-OLC-PHA | ||
| 936 | b | k | |a 44.43 |q ASE |
| 936 | b | k | |a 44.75 |q ASE |
| 951 | |a AR | ||
| 952 | |d 24 |j 2004 |e 1 |b 23 |c 12 |h 44-46 | ||